Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137694

Published: 2020